SPHK1 and pulmonary fibrosis: Moreover, the pharmacological inhibition of SPHK1 or the functional antagonism of S1PR1 disrupted fibrocyte trafficking, reduced extracellular matrix deposition, and ameliorated lung fibrosis, underscoring the therapeutic potential of targeting this pathway.